Insmed Incorporated (NASDAQ:INSM) CEO Sells $2,232,074.90 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 31,805 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $70.18, for a total value of $2,232,074.90. Following the completion of the sale, the chief executive officer now owns 379,534 shares in the company, valued at $26,635,696.12. The trade was a 7.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

William Lewis also recently made the following trade(s):

• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The shares were sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Stock Performance

Shares of NASDAQ INSM traded up $2.55 during trading hours on Thursday, reaching $72.75. 2,264,024 shares of the stock were exchanged, compared to its average volume of 2,139,833. The firm has a market capitalization of $13.01 billion, a price-to-earnings ratio of -13.11 and a beta of 1.12. The stock’s fifty day simple moving average is $71.18 and its 200 day simple moving average is $72.47. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. Insmed’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter last year, the firm earned ($1.10) EPS. Sell-side analysts predict that Insmed Incorporated will post -5.44 EPS for the current year.

Institutional Trading of Insmed

Institutional investors have recently bought and sold shares of the business. Private Advisor Group LLC bought a new stake in shares of Insmed in the second quarter valued at approximately $575,000. Federated Hermes Inc. lifted its position in shares of Insmed by 11,879.8% during the 2nd quarter. Federated Hermes Inc. now owns 10,063 shares of the biopharmaceutical company’s stock valued at $674,000 after acquiring an additional 9,979 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of Insmed during the 2nd quarter worth $449,000. Envestnet Asset Management Inc. increased its position in shares of Insmed by 211.9% in the second quarter. Envestnet Asset Management Inc. now owns 175,464 shares of the biopharmaceutical company’s stock worth $11,756,000 after purchasing an additional 119,214 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in Insmed in the second quarter valued at about $810,000.

Analysts Set New Price Targets

INSM has been the subject of a number of analyst reports. Truist Financial restated a “buy” rating and issued a $105.00 price target (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. raised their target price on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Bank of America boosted their target price on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.